v3.26.1
Research, Collaboration and Licensing Agreements
 6 Months Ended
Jun. 30, 2026
License Agreements Research Collaborations And Development Agreements [Abstract]  
Research, Collaboration and Licensing Agreements Research, Collaboration and Licensing Agreements
Revenue recognized from the Company’s strategic partnerships which includes amounts from Jazz Pharmaceuticals Ireland Limited or Jazz Pharmaceuticals, Inc. (subsidiaries of Jazz Pharmaceuticals plc, collectively referred to as “Jazz”) is summarized as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Jazz:
Development support payments$291 $475 $683 $4,968 
Drug supply for ongoing studies
791 1,841 1,136 4,798 
Other drug supply
45 — 162 2,150 
Royalties
1,589 550 2,919 752 
BeOne:
Milestone revenue
— 20,000 — 20,000 
Recognition of deferred revenue— 18,334 — 18,334 
Drug supply
1,664 7 1,664 215 
Royalties
210 19 434 19 
Bristol-Myers Squibb company, (“BMS”):
Option exercise fee— 7,500 — 7,500 
GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”):
Milestone revenue
— — — 14,000 
Daiichi Sankyo, Co., Ltd. (“Daiichi Sankyo”):
Milestone revenue
— — — 3,100 
$4,590 $48,726 $6,998 $75,836 
Since December 31, 2025, there have not been any material changes to the key terms of our collaboration and license agreements.
Contract Assets and Liabilities
As at June 30, 2026, contract assets from research, collaboration and licensing agreements were $1,799 (December 31, 2025: $2,752). As at June 30, 2026, short-term and long-term contract liabilities were $16,436 and $0, respectively (December 31, 2025: $2,418 and $14,606, respectively). Contract liabilities relate to deferred revenue from the BeOne and Jazz agreements.